首页 > 最新文献

Journal of Clinical Oncology最新文献

英文 中文
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. S1500最终总生存期分析:比较舒尼替尼与卡博赞替尼、克唑替尼和萨沃利替尼治疗晚期乳头状肾细胞癌的随机II期研究。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-09-10 DOI: 10.1200/JCO.24.00767
Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson, Vivek Narayan, Daniel J George, Daniel Y C Heng, Brian Shuch, Mark Stein, Shuchi Gulati, Maria Tretiakova, Abhishek Tripathi, Georg A Bjarnason, Peter Humphrey, Adebowale Adeniran, Ulka Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Primo N Lara, Seth P Lerner, Naomi Balzer-Haas, Sumanta K Pal

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057), cabozantinib significantly prolonged progression-free survival and improved objective response rate compared with sunitinib in patients with advanced PRCC. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized phase II, open-label trial, 147 patients with advanced PRCC who have received up to one previous therapy (excluding vascular endothelial growth factor-directed agents) were assigned to sunitinib, cabozantinib, crizotinib, or savolitinib. Ultimately, savolitinib and crizotinib arms were closed because of futility. With a median follow-up of 17.5 months, the median OS was 21.5 months (95% CI, 12.0 to 28.1) with cabozantinib and 17.3 months (95% CI, 12.8 to 21.8) with sunitinib (hazard ratio, 0.83; 95% CI, 0.51 to 1.36; P = .46). The OS landmark estimates for cabozantinib and sunitinib were 50% versus 39% at 24 months and 32% versus 28% at 36 months. In conclusion, we observed no significant difference in OS across treatment arms. Although cabozantinib represents a well-supported option for advanced PRCC, the lack of survival benefit underscores the need to develop novel therapies for this disease.

临床试验经常包括多个终点,这些终点在不同时间成熟。最初的报告通常以主要终点为基础,可能会在关键的计划共同主要分析或次级分析尚未完成时发表。临床试验更新提供了一个机会,可以传播发表在 JCO 或其他刊物上、主要终点已经报告的研究的其他结果。间充质-上皮转化(MET)信号通路在部分乳头状肾细胞癌(PRC)患者的发病机制中起着一定作用。在II期PAPMET试验(ClinicalTrials.gov标识符:NCT02761057)中,与舒尼替尼相比,卡博替尼能显著延长晚期PRC患者的无进展生存期并提高客观反应率。在此,我们将介绍最终的总生存期(OS)分析。在这项多中心、随机II期、开放标签试验中,147名既往接受过一种治疗(不包括血管内皮生长因子导向药物)的晚期PRC患者被分配到舒尼替尼、卡博赞替尼、克唑替尼或沙夫利替尼治疗方案中。最终,萨沃利替尼和克唑替尼治疗组因无效而终止。中位随访时间为17.5个月,卡博赞替尼的中位OS为21.5个月(95% CI,12.0~28.1),舒尼替尼的中位OS为17.3个月(95% CI,12.8~21.8)(危险比为0.83;95% CI,0.51~1.36;P = .46)。卡博替尼和舒尼替尼在24个月和36个月时的OS地标估计值分别为50%和39%,32%和28%。总之,我们观察到各治疗组的 OS 无明显差异。虽然卡博替尼是治疗晚期 PRCC 的一种受到广泛支持的选择,但其缺乏生存获益凸显了为这种疾病开发新型疗法的必要性。
{"title":"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.","authors":"Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson, Vivek Narayan, Daniel J George, Daniel Y C Heng, Brian Shuch, Mark Stein, Shuchi Gulati, Maria Tretiakova, Abhishek Tripathi, Georg A Bjarnason, Peter Humphrey, Adebowale Adeniran, Ulka Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Primo N Lara, Seth P Lerner, Naomi Balzer-Haas, Sumanta K Pal","doi":"10.1200/JCO.24.00767","DOIUrl":"10.1200/JCO.24.00767","url":null,"abstract":"<p><p><i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057), cabozantinib significantly prolonged progression-free survival and improved objective response rate compared with sunitinib in patients with advanced PRCC. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized phase II, open-label trial, 147 patients with advanced PRCC who have received up to one previous therapy (excluding vascular endothelial growth factor-directed agents) were assigned to sunitinib, cabozantinib, crizotinib, or savolitinib. Ultimately, savolitinib and crizotinib arms were closed because of futility. With a median follow-up of 17.5 months, the median OS was 21.5 months (95% CI, 12.0 to 28.1) with cabozantinib and 17.3 months (95% CI, 12.8 to 21.8) with sunitinib (hazard ratio, 0.83; 95% CI, 0.51 to 1.36; <i>P</i> = .46). The OS landmark estimates for cabozantinib and sunitinib were 50% versus 39% at 24 months and 32% versus 28% at 36 months. In conclusion, we observed no significant difference in OS across treatment arms. Although cabozantinib represents a well-supported option for advanced PRCC, the lack of survival benefit underscores the need to develop novel therapies for this disease.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3911-3916"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. 治疗皮质类固醇难治性硬化性慢性移植物抗宿主病的 Ruxolitinib 多中心 II 期试验。
IF 2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-08-16 DOI: 10.1200/JCO.24.00205
Vijaya Raj Bhatt, Valerie K Shostrom, Hannah K Choe, Betty K Hamilton, Krishna Gundabolu, Lori J Maness, Virender Kumar, Ram I Mahato, Lynette M Smith, Taiga Nishihori, Stephanie J Lee

Purpose: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD.

Patients and methods: In a single-arm multicenter phase II trial (N = 47), adults with sclerotic cGVHD refractory to corticosteroids and ≥one additional line of systemic therapy for cGVHD received ruxolitinib for ≥six months (ClinicalTrials.gov identifier: NCT03616184). The primary end point was complete or partial response (PR) in skin and/or joint defined according to the 2014 National Institute of Health cGVHD Consensus Criteria.

Results: Following the use of ruxolitinib for a median of 11 months, PR in skin and/or joints was noted in 49% (95% CI, 34 to 64) at 6 months, with 45% having joint and fascia response and 19% having skin response. The duration of skin/joint response was 77% (95% CI, 48 to 91) at 12 months. Overall cGVHD PR was noted in 47% (95% CI, 32 to 61). Improvement in Lee Symptom Scale summary and skin subscale scores was noted in 38% of patients. With a cumulative incidence of treatment failure of 20.8% (95% CI, 10.0 to 34.1), nonrelapse mortality (NRM) of 2.2% (95% CI, 0.17 to 10.3), and no recurrent malignancy, failure-free survival (FFS) was 77.1% (95% CI, 61.3 to 87.0) at 12 months. Ruxolitinib was overall well tolerated with no new safety signals.

Conclusion: The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.

目的:硬化性慢性移植物抗宿主病(cGVHD)是一种发病率高且难治的cGVHD,因此亟需针对硬化性cGVHD的新型疗法。本研究旨在确定鲁索利替尼对皮质类固醇难治性硬化性cGVHD患者的疗效:在一项单臂多中心II期试验(N = 47)中,皮质类固醇难治性硬化性cGVHD成人患者接受了ruxolitinib治疗≥6个月(ClinicalTrials.gov标识符:NCT03616184)。主要终点是根据2014年美国国立卫生研究院cGVHD共识标准定义的皮肤和/或关节完全或部分应答(PR):使用鲁索利替尼中位11个月后,皮肤和/或关节在6个月时出现PR的比例为49%(95% CI,34-64),其中45%有关节和筋膜反应,19%有皮肤反应。12 个月时,皮肤/关节反应持续时间为 77%(95% CI,48 至 91)。47%(95% CI,32 至 61)的患者出现了总体 cGVHD PR。38%的患者李氏症状量表(Lee Symptom Scale)总分和皮肤分量表评分有所改善。累计治疗失败发生率为20.8%(95% CI,10.0至34.1),非复发死亡率(NRM)为2.2%(95% CI,0.17至10.3),无复发恶性肿瘤,12个月时无失败生存期(FFS)为77.1%(95% CI,61.3至87.0)。Ruxolitinib总体耐受性良好,没有出现新的安全性信号:结论:在难治性硬化性 cGVHD 患者中,使用 Ruxolitinib 可获得相对较高的皮肤/关节反应率和总体 cGVHD 反应率,患者报告的结果也有所改善,NRM 较低,FFS 较高。Ruxolitinib为难治性硬化性cGVHD提供了一种有效的治疗选择。
{"title":"A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.","authors":"Vijaya Raj Bhatt, Valerie K Shostrom, Hannah K Choe, Betty K Hamilton, Krishna Gundabolu, Lori J Maness, Virender Kumar, Ram I Mahato, Lynette M Smith, Taiga Nishihori, Stephanie J Lee","doi":"10.1200/JCO.24.00205","DOIUrl":"10.1200/JCO.24.00205","url":null,"abstract":"<p><strong>Purpose: </strong>Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD.</p><p><strong>Patients and methods: </strong>In a single-arm multicenter phase II trial (N = 47), adults with sclerotic cGVHD refractory to corticosteroids and ≥one additional line of systemic therapy for cGVHD received ruxolitinib for ≥six months (ClinicalTrials.gov identifier: NCT03616184). The primary end point was complete or partial response (PR) in skin and/or joint defined according to the 2014 National Institute of Health cGVHD Consensus Criteria.</p><p><strong>Results: </strong>Following the use of ruxolitinib for a median of 11 months, PR in skin and/or joints was noted in 49% (95% CI, 34 to 64) at 6 months, with 45% having joint and fascia response and 19% having skin response. The duration of skin/joint response was 77% (95% CI, 48 to 91) at 12 months. Overall cGVHD PR was noted in 47% (95% CI, 32 to 61). Improvement in Lee Symptom Scale summary and skin subscale scores was noted in 38% of patients. With a cumulative incidence of treatment failure of 20.8% (95% CI, 10.0 to 34.1), nonrelapse mortality (NRM) of 2.2% (95% CI, 0.17 to 10.3), and no recurrent malignancy, failure-free survival (FFS) was 77.1% (95% CI, 61.3 to 87.0) at 12 months. Ruxolitinib was overall well tolerated with no new safety signals.</p><p><strong>Conclusion: </strong>The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3977-3985"},"PeriodicalIF":2.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to S. Sorscher. 答复 S. Sorscher。
IF 2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-09-11 DOI: 10.1200/JCO-24-01599
James Hadfield, Chris Abbosh, Darren Hodgson, Dan Stetson
{"title":"Reply to S. Sorscher.","authors":"James Hadfield, Chris Abbosh, Darren Hodgson, Dan Stetson","doi":"10.1200/JCO-24-01599","DOIUrl":"10.1200/JCO-24-01599","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3999-4000"},"PeriodicalIF":2.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies? 利用前瞻性随机试验的间接比较来决定黑色素瘤的治疗方案:交叉试验比较能否替代适当的正面研究?
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-10-07 DOI: 10.1200/JCO-24-01634
Kim A Margolin
{"title":"Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies?","authors":"Kim A Margolin","doi":"10.1200/JCO-24-01634","DOIUrl":"10.1200/JCO-24-01634","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3891-3894"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes. 我们能抵消局部晚期非小细胞肺癌的局部复发吗?放射剂量升级与顽固结果的 "旋转木马"。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-10-04 DOI: 10.1200/JCO-24-01448
Dawn Owen, Christina Hunter Chapman

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

肿瘤学大讲堂》系列旨在将期刊上发表的原创报告与临床相结合。在病例介绍之后,作者会描述诊断和管理方面的挑战、回顾相关文献,并总结建议的管理方法。本系列的目的是帮助读者更好地理解如何将主要研究(包括发表在《临床肿瘤学杂志》上的研究)的结果应用到自己临床实践中的患者身上。
{"title":"Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.","authors":"Dawn Owen, Christina Hunter Chapman","doi":"10.1200/JCO-24-01448","DOIUrl":"10.1200/JCO-24-01448","url":null,"abstract":"<p><p><i>The Oncology Grand Rounds series is designed to place original reports published in the</i> Journal <i>into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in</i> Journal of Clinical Oncology<i>, to patients seen in their own clinical practice.</i></p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3895-3900"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer. NRG-RTOG1106/ECOG-ACRIN 6697 的初步结果:在 III 期非小细胞肺癌中使用治疗中期 18F 氟脱氧葡萄糖定位发射断层扫描/计算机断层扫描进行个体化适应性(化疗)放疗的随机 II 期试验。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-10-04 DOI: 10.1200/JCO.24.00022
Feng-Ming Spring Kong, Chen Hu, Daniel A Pryma, Fenghai Duan, Martha Matuszak, Ying Xiao, Randall Ten Haken, Marilyn J Siegel, Lucy Hanna, Walter J Curran, Mark Dunphy, Daphna Gelblum, Morand Piert, Shruti Jolly, Clifford G Robinson, Andrew Quon, Billy W Loo, Shyam Srinivas, Gregory M Videtic, Sergio L Faria, Catherine Ferguson, Neal E Dunlap, Vijayananda Kundapur, Rebecca Paulus, Barry A Siegel, Jeffrey D Bradley, Mitchell Machtay

Purpose: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non-small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease.

Materials and methods: Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET-guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z-test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUVpeak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression.

Results: Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival (P > .4). Median SUVpeak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUVpeak and ΔMTV were not associated with FFLP (hazard ratios, 0.997; P = .395 and .461).

Conclusion: Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.

目的:NRG-RTOG0617证明了均匀大剂量放射治疗对III期非小细胞肺癌的不利影响。NRG-RTOG1106/ECOG-ACRIN6697(ClinicalTrials.gov标识符:NCT01507428)是一项随机II期试验,研究治疗中期18F-氟脱氧葡萄糖定位发射断层扫描/计算机断层扫描(FDG-PET/CT)能否指导个体化/自适应剂量强化放疗(RT),以改善和预测该病患者的预后:将适合同期化疗的患者随机分配(1:2)至标准(60 Gy/30次)或FDG-PET指导下的适应性治疗,并根据亚分期、原发肿瘤大小和组织学进行分层。所有患者都接受了治疗中期的 FDG-PET/CT;适应性治疗组患者接受了个体化、强化的增强 RT 剂量,以治疗残留的代谢活跃区。主要治疗终点是2年集中复查的无局部区域进展(FFLP),定义为计划目标体积和/或区域结节内或附近无进展。FFLP是根据修改后的意向治疗人群进行分析的,单侧Z检验显著性水平为0.15。主要影像学终点是集中审查从基线到治疗中期的SUVpeak变化;其与FFLP的关系在Cox回归的基础上使用双侧Wald检验进行评估:在138名入选患者中,127名符合条件。自适应臂患者平均接受了71 Gy的治疗,分30次进行,平均肺部剂量为17.9 Gy。集中复查的2年FFLP无明显差异(标准臂和适应臂分别为59.5%和54.6%;P = .66)。方案规定的 3 级毒性、生存期或无进展生存期无明显差异(P > .4)。适应组的中位 SUVpeak 和代谢肿瘤体积 (MTV) 从 RT 前期到 RT 中期 PET 分别下降了 49% 和 54%。然而,ΔSUVpeak和ΔMTV与FFLP无关(危险比,0.997;P = .395和.461):结论:本研究中采用的治疗中期 PET 适应性 RT 剂量升级是安全可行的,但并不能改善疗效。
{"title":"Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.","authors":"Feng-Ming Spring Kong, Chen Hu, Daniel A Pryma, Fenghai Duan, Martha Matuszak, Ying Xiao, Randall Ten Haken, Marilyn J Siegel, Lucy Hanna, Walter J Curran, Mark Dunphy, Daphna Gelblum, Morand Piert, Shruti Jolly, Clifford G Robinson, Andrew Quon, Billy W Loo, Shyam Srinivas, Gregory M Videtic, Sergio L Faria, Catherine Ferguson, Neal E Dunlap, Vijayananda Kundapur, Rebecca Paulus, Barry A Siegel, Jeffrey D Bradley, Mitchell Machtay","doi":"10.1200/JCO.24.00022","DOIUrl":"10.1200/JCO.24.00022","url":null,"abstract":"<p><strong>Purpose: </strong>NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non-small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease.</p><p><strong>Materials and methods: </strong>Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET-guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided <i>Z</i>-test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUV<sub>peak</sub> from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression.</p><p><strong>Results: </strong>Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; <i>P</i> = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival (<i>P</i> > .4). Median SUV<sub>peak</sub> and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUV<sub>peak</sub> and ΔMTV were not associated with FFLP (hazard ratios, 0.997; <i>P</i> = .395 and .461).</p><p><strong>Conclusion: </strong>Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3935-3946"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. 勘误:治疗复发性/难治性多发性骨髓瘤的 Linvoseltamab。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-10-15 DOI: 10.1200/JCO-24-02169
{"title":"Erratum: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.","authors":"","doi":"10.1200/JCO-24-02169","DOIUrl":"10.1200/JCO-24-02169","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"4001"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). 奥沙利铂联合氟嘧啶/贝伐单抗作为老年不可切除转移性结直肠癌的初始疗法:一项多中心、随机、开放标签 III 期试验(JCOG1018)。
IF 2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-08-26 DOI: 10.1200/JCO.23.02722
Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, Seiji Hasegawa, Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu, Yasuhiro Shimada

Purpose: Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population.

Methods: This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145).

Results: Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm.

Conclusion: No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.

目的:氟嘧啶(FP)和奥沙利铂(OX)加贝伐单抗(BEV)的双联化疗是治疗不可切除转移性结直肠癌(MCRC)的标准方案。然而,在FP+BEV(FP+BEV)中加入OX对老年患者的疗效仍不明确,而老年患者是FP+BEV的标准人群。我们的目的是确认在 FP + BEV 的基础上添加 OX 对这一人群的优越性:这项开放标签、随机的 III 期试验在日本 42 家医疗机构进行。年龄在 70-74 岁、东部合作肿瘤学组表现状态(ECOG-PS)为 2 和 75 岁及以上、ECOG-PS 为 0-2 的不可切除 MCRC 患者被随机分配(1:1)到 FP + BEV 组或添加 OX(FP + BEV + OX)组。入组前声明使用氟尿嘧啶加左亚叶酸钙或卡培他滨。主要终点是无进展生存期(PFS)。该研究已在日本临床试验注册中心注册(标识符:jRCTs031180145):2012年9月至2019年3月,251名患者被随机分配到FP+BEV组(125人)和FP+BEV+OX组(126人)。两组患者的中位年龄分别为 80 岁和 79 岁。FP + BEV 组的中位 PFS 为 9.4 个月(95% CI,8.3 至 10.3),FP + BEV + OX 组为 10.0 个月(9.0 至 11.2)(危险比 [HR],0.84 [90.5% CI,0.67 至 1.04];单侧 P = .086)。FP+BEV治疗组的中位总生存期为21.3个月(18.7至24.3个月),FP+BEV+OX治疗组的中位总生存期为19.7个月(15.5至25.5个月)(HR,1.05 [0.81至1.37])。FP+BEV+OX治疗组发生≥3级不良事件的比例更高(52%对69%)。FP+BEV组有1例治疗相关死亡,FP+BEV+OX组有3例:结论:在MCRC老年患者的一线治疗中,在FP + BEV的基础上加用OX并无益处。建议在这一人群中使用 FP + BEV。
{"title":"Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).","authors":"Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, Seiji Hasegawa, Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu, Yasuhiro Shimada","doi":"10.1200/JCO.23.02722","DOIUrl":"10.1200/JCO.23.02722","url":null,"abstract":"<p><strong>Purpose: </strong>Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population.</p><p><strong>Methods: </strong>This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145).</p><p><strong>Results: </strong>Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided <i>P</i> = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% <i>v</i> 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm.</p><p><strong>Conclusion: </strong>No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3967-3976"},"PeriodicalIF":2.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. 小细胞肺癌的全身治疗:ASCO 指南快速建议更新。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 DOI: 10.1200/JCO-24-02245
Gregory P Kalemkerian, Humera Khurshid, Nofisat Ismaila

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

ASCO 快速建议更新强调了对选定的 ASCO 指南建议的修订,以应对新出现的和改变实践的数据。快速更新得到了证据审查的支持,并遵循《ASCO 指南方法手册》中概述的指南制定流程。这些文章的目的是及时传播最新的建议,以便更好地向医疗从业人员和公众介绍现有的最佳癌症治疗方案。指南和更新并不打算取代临床医生的独立专业判断,也不考虑患者之间的个体差异。有关免责声明和其他重要信息,请参见附录(附录 1 和附录 2,仅在线提供)。
{"title":"Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.","authors":"Gregory P Kalemkerian, Humera Khurshid, Nofisat Ismaila","doi":"10.1200/JCO-24-02245","DOIUrl":"https://doi.org/10.1200/JCO-24-02245","url":null,"abstract":"<p><p><i>ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only)</i>.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2402245"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials. 行业赞助的癌症临床试验与联邦政府赞助的癌症临床试验的患者注册情况。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-20 Epub Date: 2024-09-27 DOI: 10.1200/JCO.24.00843
Joseph M Unger, Hong Xiao, Riha Vaidya, Michael LeBlanc

Purpose: The conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally-sponsored trials examine a broad set of research questions that are not typically addressed by industry; these trials, which are also more commonly conducted in diverse populations, were recently shown to have contributed to gains of 14 million life-years for patients with cancer. Despite the different mandates, the proportion of patients who might participate in industry-sponsored versus federally-sponsored cancer studies is unknown.

Methods: We evaluated trial enrollment patterns from 2008 to 2022 using ClinicalTrials.gov data. The ratio of enrollments attributable to industry versus federal sponsors was estimated. A large set of estimates on the basis of different combinations of study characteristics were generated. Point estimates were determined as the mean of combinations and confidence limits by the IQR. Five-year intervals were examined to smooth annual variation.

Results: In total, N = 26,080 studies were examined. The estimated enrollment ratio from 2018 to 2022 for all industry-sponsored versus federally-sponsored trials was 8.1 (IQR, 6.2-9.9). For adult trials, the ratio increased from 4.8 (IQR, 4.4-5.3) during 2008-2012 to 9.6 (IQR, 7.4-11.8) during 2018-2022; for trials in children, the ratio increased from 0.7 (IQR, 0.6-0.7) to 2.3 (IQR, 1.8-2.7). Despite increasing cancer incidence, enrollment counts for federally-sponsored trials were flat over the study period.

Conclusion: In the United States, there is a growing reliance on industry to conduct cancer clinical research. Underinvestment in federally-sponsored research comes at a cost for both patients and researchers, with lost opportunities for scientific, clinical, and population advances.

目的美国癌症临床研究的开展得到了私人和公共赞助商的支持。产业界的目标是获得新药批准。联邦赞助的试验研究一系列广泛的研究问题,而这些问题通常不是由企业解决的;这些试验也更多地在不同人群中进行,最近的研究表明,这些试验为癌症患者赢得了 1,400 万年的生命。尽管规定不同,但可能参与行业赞助与联邦赞助癌症研究的患者比例尚不清楚。方法我们使用 ClinicalTrials.gov 数据评估了 2008 年至 2022 年的试验注册模式。我们估算了行业赞助者与联邦赞助者的注册比例。根据研究特征的不同组合得出了大量的估计值。点估算值为组合的平均值,置信区间为 IQR。对五年区间进行了研究,以平滑年度变化。从 2018 年到 2022 年,所有行业赞助的试验与联邦政府赞助的试验的估计注册比率为 8.1(IQR,6.2-9.9)。对于成人试验,该比率从2008-2012年的4.8(IQR,4.4-5.3)上升到2018-2022年的9.6(IQR,7.4-11.8);对于儿童试验,该比率从0.7(IQR,0.6-0.7)上升到2.3(IQR,1.8-2.7)。尽管癌症发病率不断上升,但在研究期间,联邦政府赞助的试验的注册人数却保持平稳。联邦政府赞助的研究投资不足,患者和研究人员都付出了代价,失去了科学、临床和人口进步的机会。
{"title":"Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials.","authors":"Joseph M Unger, Hong Xiao, Riha Vaidya, Michael LeBlanc","doi":"10.1200/JCO.24.00843","DOIUrl":"10.1200/JCO.24.00843","url":null,"abstract":"<p><strong>Purpose: </strong>The conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally-sponsored trials examine a broad set of research questions that are not typically addressed by industry; these trials, which are also more commonly conducted in diverse populations, were recently shown to have contributed to gains of 14 million life-years for patients with cancer. Despite the different mandates, the proportion of patients who might participate in industry-sponsored versus federally-sponsored cancer studies is unknown.</p><p><strong>Methods: </strong>We evaluated trial enrollment patterns from 2008 to 2022 using ClinicalTrials.gov data. The ratio of enrollments attributable to industry versus federal sponsors was estimated. A large set of estimates on the basis of different combinations of study characteristics were generated. Point estimates were determined as the mean of combinations and confidence limits by the IQR. Five-year intervals were examined to smooth annual variation.</p><p><strong>Results: </strong>In total, N = 26,080 studies were examined. The estimated enrollment ratio from 2018 to 2022 for all industry-sponsored versus federally-sponsored trials was 8.1 (IQR, 6.2-9.9). For adult trials, the ratio increased from 4.8 (IQR, 4.4-5.3) during 2008-2012 to 9.6 (IQR, 7.4-11.8) during 2018-2022; for trials in children, the ratio increased from 0.7 (IQR, 0.6-0.7) to 2.3 (IQR, 1.8-2.7). Despite increasing cancer incidence, enrollment counts for federally-sponsored trials were flat over the study period.</p><p><strong>Conclusion: </strong>In the United States, there is a growing reliance on industry to conduct cancer clinical research. Underinvestment in federally-sponsored research comes at a cost for both patients and researchers, with lost opportunities for scientific, clinical, and population advances.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3917-3925"},"PeriodicalIF":42.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1